By Jorge L. Contreras On July 2, 2024, the High Court of the United Kingdom issued a decision in Moderna’s mRNA vaccine patent litigation against Pfizer and BioNTech. As I previously discussed in October of 2020, Moderna pledged not to enforce its patents against makers of COVID-19 vaccines during the pandemic. Then, in 2022, Moderna…
Heightened Scrutiny of Your Royal Highness By Bobby Stroup On Sunday, March 10, tabloids were in quite a frenzy when the British royal family published a photoshopped picture of Catherine, princess of Wales. The hubbub was extra hubbubbly, because this was the first official photo after the princess had abdominal surgery this past January. The…
Does organoid intelligence warrant recognition for the work it produces? And is that output protectible?
This piece identifies three interrelated topics that warrant scrutiny as drivers of psychedelic racial health inequities.
Here, we examine hype in the context of a perennial tension at the heart of patenting communication: between advertising innovation and keeping it secret.
A brief sketch of the potential for Rights of Nature legislation to safeguard sacred plant medicines by recognizing them as rights holders unto themselves.
This concluding post attempts to synthesize contributions to the symposium “From Principles to Practice: Human Rights and Public Health Emergencies”
Neglected tropical diseases were at the forefront of a recent convening on human health and climate change.
Scholars, analysts, and companies cannot agree on what Amgen v. Sanofi means for patients, drug makers, and innovation.
SCOTUS revisits enablement, but Amgen v. Sanofi probably won’t transform patent law on its own.
